製品名:1-(oxan-2-yl)-1H-pyrazole

IUPAC Name:1-(oxan-2-yl)-1H-pyrazole

CAS番号:449758-17-2
分子式:C8H12N2O
純度:98%+
カタログ番号:CM104631
分子量:152.2

包装単位 有効在庫 価格(USD) 数量
CM104631-100g in stock ŭȀ
CM104631-500g in stock ǕƩƩ

研究開発用専用.

問い合わせフォーム

   refresh    

製品詳細

CAS番号:449758-17-2
分子式:C8H12N2O
融点:-
SMILESコード:C1CCC(OC1)N1C=CC=N1
密度:
カタログ番号:CM104631
分子量:152.2
沸点:269.7°C at 760 mmHg
MDL番号:MFCD11044692
保管方法:2-8°C

Category Infos

Pyrazoles
Pyrazoles are organic compounds of the general formula C3H3N2H. It is a five-membered heterocycle consisting of three carbon atoms and two adjacent nitrogen atoms. As an H-bond-donating heterocycle, pyrazole has been used as a more lipophilic and metabolically more stable bioisomer of phenol. Pyrazoles have attracted more and more attention due to their broad spectrum of action and strong efficacy.
Pyrazone
Custom pyrazone for customers from all over the world are our main business.
Tetrahydropyrans
Tetrahydropyran is an organic compound consisting of a saturated six-membered ring containing five carbon atoms and one oxygen atom. Tetrahydropyrans are common structural motifs in natural products and synthetic therapeutic molecules. In nature, these six-membered oxygen heterocycles are usually assembled by intramolecular reactions, including oxygen Michael addition or ring opening of epoxy alcohols. In fact, polyether natural products have been particularly extensively studied for their fascinating structures and important biological properties; these are often formed through endoselective epoxy open cascades.

Column Infos

Pyrans
Pyrans are an important class of six-membered heterocyclic compounds, non-aromatic rings, composed of five carbon atoms and one oxygen atom, and contain two double bonds. The molecular formula of pyran is C5H6O, and there are two isomers. Pyrans, together with benzo derivatives, form scaffolds for a variety of drug applications, many of which are approved and promising candidates in clinical trials and recently isolated bioactive natural products.
Asciminib
Novartis Scemblix® FDA approved in newly diagnosed CML, offering superior efficacy, and favorable safety and tolerability profile. Scemblix now approved for newly diagnosed and previously treated CML, allowing four times the patients access to potential new standard of care.
Scemblix is an orally available tyrosine kinase inhibitor that works by blocking the BCR-ABL1 fusion protein, a known hallmark of certain leukemias. The drug was first approved for CML three years ago, winning two indications. The first is for the treatment of Philadelphia chromosome-positive, chronic phase CML, for which the drug was given accelerated approval. The second is a full approval for the same patient population, with the additional specification that they carry the T315I mutation.